GlassScriptPhysician profile
Mary Leyva
NPI 1578543658
$2,276.11
in general payments reported to CMS, 2019-2025
18 companies · $520 in 2025
The $520 reported for 2025 was more than what 96% of Advanced Practice Midwife providers received nationally (typical 2025 total: $70.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $401 · 2022: $461 · 2023: $483 · 2024: $410 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,413.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $504.50 | 2021-2024 | |
| Astellas Pharma US INC | $413.32 | 2022-2025 | Veozah |
| Biogen, INC. | $289.75 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $152.78 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $133.58 | 2023 | Myfembree |
| Mayne Pharma Commercial LLC | $111.15 | 2021-2022 | |
| Daiichi Sankyo INC. | $108.57 | 2021-2022 | |
| Hologic Sales and Service, LLC | $98.62 | 2022-2025 | Thinprep 2000 Processor, Aptima |
| Evofem Biosciences, INC. | $90.73 | 2024-2025 | Solosec, Phexx, Phexxi |
| Smith+Nephew, INC. | $87.38 | 2023-2025 | Stravix, Grafix |
| Millicent US INC | $65.19 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Organon LLC | $62.40 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $59.07 | 2021-2024 | Gardasil 9, Gardasil |
| Cepheid | $25.18 | 2025 | Genexpert |
| Shield Therapeutics INC | $21.45 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $18.65 | 2025 | Paragard T 380a |
| Amgen INC. | $17.42 | 2025 | Evenity |
| Exeltis, USA INC. | $16.37 | 2024 | Slynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Leyva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.